STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page1 Lines1-2	Abstract/Para 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page2 Line34-48	Abstract/Para 3-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	P5 Lines72-83, P6 Lines 111-115	Intro/Para 1-5
Objectives	3	State specific objectives, including any prespecified hypotheses	P7 Lines116-120	Intro/Para 5
Methods				
Study design	4	Present key elements of study design early in the paper	P7 Line 126	Methods/Para 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P7 Line 126-134	Methods/Para 1
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	NA (This is a case only study)	NA
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	NA (This is a case only study)	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P8 Lines 155- P10 Line 203	Methods/Para 5-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P8 Lines 156-159, P9 Lines 164-170	Methods/Para 5-6
Bias	9	Describe any efforts to address potential sources of bias	P9 Lines 176- P10 Line	Methods/Para 7-9
Study size	10	Explain how the study size was arrived at	P7 Lines 126-127	Methods/Para 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P10 Line 206- P11 Line 225	Methods/Para 10-11

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P10 Line 206- P11 Line	Methods/Para 10-11
		(b) Describe any methods used to examine subgroups and interactions	NA (No subgroup	NA
		(c) Explain how missing data were addressed	P9 Lines 172-174	Methods/Para 7
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	NA (This is a case only study. All cases are accounted for.)	NA
		(e) Describe any sensitivity analyses	NA (no sensitivity	NA
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P12 Lines 229-248	Results/Para 1-4
		(b) Give reasons for non-participation at each stage	NA (This is a case only	NA
		(c) Consider use of a flow diagram	NA (This is a case only	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P12 Lines 229-248	Results/Para 1-4
		(b) Indicate number of participants with missing data for each variable of interest	Results/Para 1-4	Results/Para 1-4
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	NA (This is a case only	NA
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	NA (This is a case only	NA
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	NA (This is a case only	NA
		Cross-sectional study—Report numbers of outcome events or summary measures	NA (This is a case only	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P13 Lines 262-266, P14 Lines 280-281	Results/Para 7-8
		(b) Report category boundaries when continuous variables were categorized	P13 Lines 261-271	Results/Para 7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA (This study does not	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA (No subgroups or	NA
Discussion				
Key results	18	Summarise key results with reference to study objectives	P14 Lines 1288-294	Discussion/Para 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P16 Line 342- P18 Line 367	Discussion/Para 6

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P14 Line 295- P16 Line 341, P18 Lines 370-387	Discussion/Para 2-5, Conclusion/Para 1
Generalisability	21	Discuss the generalisability (external validity) of the study results	P16 Lines 342-346	Discussion/Para 6
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P19 Lines 390-395	Acknowledgments/Para 1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/jtd-23-533
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.